Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Short Interest Up 24.8% in March
by Renee Jackson · The Cerbat GemZimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 10,000,836 shares, a growth of 24.8% from the March 15th total of 8,016,066 shares. Based on an average trading volume of 1,963,892 shares, the short-interest ratio is currently 5.1 days. Approximately 5.2% of the shares of the company are sold short.
Analyst Ratings Changes
ZBH has been the subject of a number of recent analyst reports. Sanford C. Bernstein lifted their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research note on Friday, January 9th. Barclays cut their price target on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a research note on Thursday, February 12th. Citigroup restated a “buy” rating on shares of Zimmer Biomet in a research note on Wednesday, February 11th. The Goldman Sachs Group downgraded shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a report on Friday, January 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $105.95.
Check Out Our Latest Research Report on Zimmer Biomet
Insider Activity at Zimmer Biomet
In other news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.28% of the stock is owned by insiders.
Institutional Investors Weigh In On Zimmer Biomet
A number of hedge funds have recently modified their holdings of ZBH. Rakuten Investment Management Inc. acquired a new stake in Zimmer Biomet during the third quarter worth about $37,307,000. Sector Gamma AS increased its position in Zimmer Biomet by 28.0% during the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock worth $11,178,000 after purchasing an additional 24,847 shares during the last quarter. SG Americas Securities LLC increased its position in Zimmer Biomet by 29.2% during the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after purchasing an additional 13,812 shares during the last quarter. Border to Coast Pensions Partnership Ltd increased its position in shares of Zimmer Biomet by 6.5% during the third quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock valued at $35,506,000 after acquiring an additional 22,104 shares during the last quarter. Finally, National Pension Service increased its position in shares of Zimmer Biomet by 4.5% during the third quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock valued at $38,757,000 after acquiring an additional 16,928 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.
Zimmer Biomet Price Performance
ZBH traded up $0.59 during midday trading on Thursday, hitting $94.79. 898,672 shares of the company traded hands, compared to its average volume of 2,180,103. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $18.35 billion, a price-to-earnings ratio of 26.78, a PEG ratio of 1.97 and a beta of 0.61. Zimmer Biomet has a 52-week low of $84.59 and a 52-week high of $108.29. The business has a 50 day simple moving average of $93.44 and a two-hundred day simple moving average of $93.32.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s revenue was up 10.9% compared to the same quarter last year. During the same period last year, the firm posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.
Zimmer Biomet Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is 27.12%.
Zimmer Biomet Company Profile
Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.
The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.